Proton pump inhibitors and acid-related diseases

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 22-37

  Sachs, George ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; ATROPHIC GASTRITIS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; TREATMENT PLANNING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMPS;

EID: 0031017338     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Naik SR, Bajaj SC, Goyal RK, et al. Parietal cell mass in healthy human stomach. Gastroenterology 1971;61:682-5.
2. Dent J. Roles of gastric acid and pH in the pathogenesis of gastroesophageal reflux disease. Scand J Gastroenterol 1994;29(suppl 201):55-61.
3. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
4. Goddard A, Logan R. One week low dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995;7:1-3.
5. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating H. pylori. Am J Gastroenterol 1992;87:1716.
6. Ghiara P, Marchetti M, Blaser MJ, et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immunol 1995;63:4154-60.
7. Tache Y. Central nervous system regulation of acid secretion. In: Johnson LR, ed. Physiology of the gastrointestinal tract, 2nd ed, vol 2. New York: Raven Press, 1987:911-30.
8. Surprenant A. Control of the gastrointestinal tract by enteric neurons. Annu Rev Physiol 1994;56:117-40.
9. DelValle J, Yamada T. Amino acids and amines stimulate gastrin release from canine antral G-cells via different pathways. J Clin Invest 1990;85:139-43.
10. Schepp W, Prinz C, Hakanson R, et al. Bombesin-like peptides stimulate gastrin release from isolated rat G-cells. Regul Pept 1990;28:241-53.
11. Costa M, Furness JB. Structure and neurochemical organization of the enteric nervous system. In: Schultz SG, Makhlouf GM, eds. Handbook of physiology. The gastrointestinal system II. Bethesda, MD: American Physiological Society, 1989:97-110.
12. Walsh J, Grossman M. Medical progress: gastrin. N Engl J Med 1975;292:1324-32.
13. Prinz CM, Kajimura M, Scott DR, et al. Histamine secretion from rat enterochromaffin-like cells. Gastroenterology 1993;105:449-61.
14. Zeng N, Bayle DB, Walsh JH, Kang T, Sachs G. Localisation of PACAP receptors on rat fundic ECL and D cells. Gastroenterology 1996;110:A1136.
15. Prinz C, Scott DR, Hurwitz D, et al. Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am J Physiol 1994;267:G663-75.
16. Zeng N, Walsh JH, Kang T, et al. PYY inhibition of rat gastric cell ECL cell function. Gastroenterology In press.
17. Prinz C, Sachs G, Walsh JH, et al. The somatostatin receptor subtype on rat enterochromaffin-like cells. Gastroenterology 1994;107:1067-74.
18. Larsson H, Carlsson E, Mattsson H. Plasma gastrin in gastric enterochromaffin-like cell activation and proliferation: studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391-9.
19. Gustavsson S, Lundquist G. Participation of antral somatostatin in the local regulation of gastrin release. Acta Endocrinol 1978;88:339-46.
20. Yamada T, Chiba T. Somatostatin. In: Schultz SG, Makhlouf GM, eds. Handbook of physiology. The gastrointestinal system II. Bethesda, MD: American Physiological Society, 1989:431-53.
21. Lewin MJ. The somatostatin receptor in the GI tract. Annu Rev Physiol 1992;54:455-68.
22. Lloyd KCK, Raybould HE, Walsh JH. Cholecystokinin inhibits gastric acid secretion through type A cholecystokinin receptors and somatostatin in rats. Am J Physiol 1985;248:G569-73.
23. DelValle J, Chiba T, Park J, Yamada T. Distinct receptors for cholecystokinin gastrin on canine fundic D-cells. Am J Physiol 1993;264:G811-15.
24. + ATPase. Am J Physiol 1983;245: G589-96.
25. +-ATPase membranes. Am J Physiol 1984;246:C537-45.
26. Kajimura M, Reuben MA, Sachs G. The muscarinic receptor gene expressed in rabbit parietal cells is the M3 subtype. Gastroenterology 1992;103:870-87.
27. Pfeiffer A, Rochlitz H, Noelke B, et al. Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology 1990;98:218-22.
28. 2-receptors. Nature 1972;236: 385-90.
29. Chew CS, Hersey SJ, Sachs G, Berglindh T. Histamine responsiveness of isolated gastric glands. Am J Physiol 1980;238:G312-20.
30. 2+]i in parietal cells depends on cAMP. Gastroenterology 1995;109:1060-7.
31. Konturek SJ, Cieszkowski M, Jaworek J, et al. Effects of epidermal growth factor on gastrointestinal secretions. Am J Physiol 1984;246:G580-6.
32. Hirschowitz BI, Fong J, Molina E. Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog. J Pharmacol Exp Ther 1983;225:263-8.
33. Hui WM, Lam SK, Lok AS, et al. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. Am J Med 1992;92:265-74.
34. 2-receptor antagonist. J Int Med Res 1975;3:86-92.
35. 2 receptor. Proc Natl Acad Sci U S A 1991;88:5937-42.
36. Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4(suppl 1):29-45.
37. Blevins GT, Westerlo E, Yule DI, Williams J. Characterization of choleycstokinin receptor agonist activity by a family of cholecystokinin receptor antagonists. J Pharmacol Exp Ther 1994;269:911-15.
38. Kraut JA, Birmingham S, Sachs G, Reuben MA. Expression of gastric and colonic H-K ATPase in the rat kidney. Am J Physiol 1995;268:F581-7.
39. +)-ATPase. J Biol Chem 1986;261:16788-91.
40. Reuben MA, Lasater LS, Sachs G. Characterization of a β subunit of the gastric H/K-transporting ATPase. Proc Natl Acad Sci U S A 1990;87:6767-71.
41. DeTomaso AW, Blanco G, Mercer RW. The alpha and beta subunits of the Na,K-ATPase can assemble at the plasma membrane into functional enzyme. J Cell Biol 1994;127: 55-69.
42. Glynn IM, Karlish SJD. Occluded cations in active transport. Annu Rev Biochem 1990;59:171-205.
43. Lindberg P, Nordberg O, Alminger T, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 1986;29:1327-9.
44. +-adenosine triphosphatase. Biochemistry 1993;32:2345-55.
45. + ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
46. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993;7(suppl 1):4-12.
47. +-ATPase. Biochim Biophys Acta 1983;1148:223-33.
48. Bamberg K, Sachs G. Topological analysis of the H,K-ATPase by in vitro translation. J Biol Chem 1994;269:16909-19.
49. Shin JM, Sachs G. Identification of a region of the H,K-ATPase a subunit associated with the β subunit. J Biol Chem 1994;269:8642-6.
50. +) ATPase. Nature 1981;290:159-61.
51. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
52. Dobrilla G, Di Fede F. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clin Ther 1993;15(suppl B):2-13.
53. Fitton A, Wiseman L. Pantoprazole, a review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
54. Andersen JP, Vilsen B. Structure function relationships of cation translocation by Ca and Na,K ATPases studied by site directed mutagenesis. FEBS Lett 1995;359:101-6.
55. Lutsenko S, Kaplan JH. Organization of P-type ATPases: significance of structural diversity. Biochemistry 1995;34:15607-13.
56. +)-ATPase inhibitors, omeprazole and E3810. J Biol Chem 1993;268:21553-9.
57. Gedda K, Scott D, Besancon M, et al. The turnover of the gastric H, K-ATPase a subunit and its relationship to inhibition of gastric acid secretion. Gastroenterology 1995;109:1134-41.
58. Lind T, Cederberg C, Ekenved G, et al. Effect of omeprazole, a gastric acid pump inhibitor on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-8.
59. Regardh CG, Gabrielsson M, Hoffman KJ, et al. Pharmacokinetics and metabolism of omeprazole in animals and man. Scand J Gastroenterol 1985;20:79-94.
60. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.
61. Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24 hr intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984;19:916-22.
62. Sachs G, Carlsson E, Lindberg P, Wallmark B. Gastric H,K-ATPase as therapeutic target. Annu Rev Pharmacol Toxicol 1988;28:269-84.
63. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-51.
64. Bell NJ, Burget D, Howden CW, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl):59-67.
65. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
66. Rune SJ. Treatment strategies for symptom resolution, healing and Helicobacter pylori eradication in duodenal ulcer patients. ScandJ Gastroenterol 1994;205(suppl):45-7.
67. 2 receptor antagonists: a controlled clinical trial. Gut 1991;32(suppl 4):435-8.
68. Bell GD, Bate CM, Axon AT, et al. Addition of metronidazole to omeprazole/amoxycillin - dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Aliment Pharmacol Ther 1995;9:513-20.
69. Garnett WR. Efficacy, safety and cost issues in managing patients with gastroesophageal reflux disease. Am J Hosp Pharm 1993;50:S11-18.
70. 2 receptor antagonists with lansoprazole, a new H, K-ATPase inhibitor: a controlled double blind study. Am J Gastroenterol 1993;88:1212-17.
71. Koop H, Schepp W, Damman HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis: results of a German multicenter study. J Clin Gastroenterol 1995;20:192-5.
72. Cooperative Study Group. Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing and recurrence. Br Med J 1984;289:525-8.
73. Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993;34:1458-62.
74. Judmaier G, Koelz HR. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 1994;8:81-6.
75. Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
76. Arens MJ, Dent J. Acid pump blockers: what are their current therapeutic roles? Baillieres Clin Gastroenterol 1993;7:95-128.
77. Witzel L, Gutz H, Hutteman W. Pantoprazole vs omeprazole in treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995;9:19-24.
78. Hirschowitz BI. Non-steroidal anti-inflammatory drugs and the gastro-intestinal tract. Gastroenterologist 1994;2:207-23.
79. Metz DC, Pisegna JR, Fishbeyn VA, et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993;17:468-80.
80. Arnold R. Which indications for proton pump inhibitors? Fortschr Med 1994;1112:44-5.
81. Mattsson H, Havu N, Brautigam J, et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 1991;100:311-19.
82. Lamberts R, Creutzfeldt W, Strueber HG, et al. Long-term omeprazole therapy in peptic ulcer disease. Gastrin, endocrine cell growth and gastritis. Gastroenterology 1993;104:1356-63.
83. Barrett P, Hobbs RC, Coates PJ, et al. Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J 1995;27:482-6.
84. Burlinson B, Morriss SH, Gatehouse DG, et al. Genotoxicity studies of gastric acid inhibitory drugs. Lancet 1990; 335:419-20.
85. Burlinson B, Morriss S, Gatehouse DG, et al. Uptake of tritiated thymidine by cells of the rat gastric mucosa after exposure to loxtidine or omeprazole. Mutagenesis 1991;6: 11-18.
86. Scott D, Reuben M, Zampighi G, Sachs G. Cell isolation genotoxicity assessment in gastric mucosa. Dig Dis Sci 1990;35:1217-25.
87. Smallwood RA, Berlin RG, Castagnoli N, et al. Safety of acid suppressing drugs. Dig Dis Sci 1994;40(suppl):63-80.
88. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1990;6:773-7.
89. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
90. Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995;267:1655-8.
91. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
92. National Institutes of Health. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
93. Clyne M, Labigne A, Drumm B. Helicobacter pylori requires an acidic environment to survive in the presence of urea. Infect Immunol 1995;631:669-73.
94. Mobley HLT, Island MD, Hausinger RP. Molecular biology of microbial ureases. Microbiol Rev 1995;59:451-80.
95. Parma DH, Snyder M, Soboloevski S, Nawroz M, Gold L. The rex system of bacteriophage lambda and altruistic cell death. Genes Dev 1992;6:497-510.
96. Mitchell P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol Rev 1966;41:445-502.
97. Meyer-Rosberg K, Scott DR, Melchers K, et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996;111:886-900.
98. Eaton KA, Morgan DR, Brooks CL, et al. Essential role of urease in the pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immunol 1991;59:2470-5.
99. Tsuda M, Karita M, Morshed MG, et al. A urease negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach. Infect Immunol 1994;62:3586-9.
100. Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995;37:39-43.
101. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and esophageal reflux disease. Scand J Gastroenterol 1994; 29(suppl 201):79-82.
102. Lee A, Dixon MF, Danon SJ, et al. Local acid production Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995;7:461-5.
103. Morgan DR, Freedman F, Depew CE, Kraft WG. Growth of Campylobacter in liquid media. J Clin Microbiol 1987;25:2123-5.
104. Hui WM, Chen BW, Cho CH, Luk CT, Lam SK. Role of gastric mucosal blood flow in cytoprotection. Digestion 1991;48:113-20.
105. Yousfi MM, El-Zimaity HMT, Cole RA, et al. Metronidazole, omeprazole clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:209-12.
106. Burette A, Glupczynski Y, Deprez C, et al. Lansoprazole plus roxythromycin and metronidazole for eradication of H. pylori. Gastroenterology 1993;104:A49.
107. Webb DD, Ciociola AA, Perschy TB, et al. Effect of administration of ranitidine bismuth citrate with food on the suppression and eradication of Helicobacter pylori in infected volunteers. Am J Gastroenterol 1995;90:1273-7.
108. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992;13:357-68.
109. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The MACH 1 study: optimal 1 week treatment for H. pylori defined? [abstr] Gut 1995;37(suppl 1):A4.
110. +-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1, 2α)imidazole. J Biol Chem 1987;262: 2077-84.
111. Ife RJ, Brown TH, Keeling DJ, et al. Reversible inhibitors of the gastric H,K-ATPase. 3-substituted-4-(phenylamino) quinolines. J Med Chem 1992;35:3413-22.
112. Corthesy-Theulaz I, Porta N, Glauser M, et al. Oral immunization with Helicobacter pylori urease β subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995;109:115-21.